A Major Shift in How Patients Access GLP-1 Medications
The shortages of brand-name GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) over the past few years created a vast gray market of compounded versions — semaglutide, tirzepatide, and other GLP-1 receptor agonists prepared by compounding pharmacies and sold through telehealth platforms, medical spas, and other outlets, often at substantially lower prices.
The result has been hundreds of thousands of patients receiving compounded GLP-1 medications. Many have done well. Others have experienced complications related to dosing errors, contamination, or unverified ingredients. The regulatory landscape has continued to evolve.
At Zimmer Medical Group, we believe patients deserve clear information about the differences, risks, and current options.
The Basic Distinction
FDA-Approved Branded Medications
- Ozempic, Wegovy, Rybelsus — semaglutide (Novo Nordisk)
- Mounjaro, Zepbound — tirzepatide (Eli Lilly)
- Manufactured under strict FDA quality controls
- Dosed in standardized devices (pens)
- Active ingredient identity, purity, and concentration verified
- Sterility ensured
- Backed by extensive clinical trial data
- Covered by insurance for approved indications (with prior authorization complexities)
Compounded Versions
- Prepared by compounding pharmacies (501a or 503b)
- May contain semaglutide or tirzepatide
- May contain salt forms (semaglutide acetate, semaglutide sodium) that have not been studied
- Often combined with other substances (B12, B vitamins, lipotropics)
- Variable quality control depending on the pharmacy
- Not FDA-approved
- Typically dosed by drawing from vials (more error-prone than pens)
- Lower cost — often $200–500 per month vs. $1000+ for branded
Why Compounding Was Allowed
Federal law (Section 503A of the Federal Food, Drug, and Cosmetic Act) permits pharmacies to compound drugs that are otherwise FDA-approved when:
- The drug appears on the FDA shortage list, OR
- The compounded version is meaningfully different (different strength, different formulation needed for an individual patient who cannot use the standard product)
When semaglutide and tirzepatide were on the FDA shortage list, large-scale compounding was permitted. As the shortages resolved, the regulatory situation changed.
Recent Regulatory Changes
The FDA removed semaglutide and tirzepatide from the official shortage list in 2024–2025. This has significant implications:
- Large-scale compounding for the purpose of avoiding the shortage is no longer allowed
- Compounding may still be allowed in limited circumstances for individual patients with specific clinical needs
- Many compounding operations have been required to wind down
- Enforcement and legal challenges are ongoing
The landscape continues to evolve, and patients should be aware that what was widely available a year ago may not be legally compounded today.
Specific Concerns With Compounded Versions
Variable Active Ingredient
- Reports of compounded products containing the wrong amount of active ingredient
- Some products have been found to contain salt forms (semaglutide sodium, semaglutide acetate) that differ from what the FDA approved
- The clinical effects of these salt forms are not fully studied
- The FDA has issued warnings about specific compounded products
Dosing Errors
- Compounded vials require patients to draw their own doses
- Concentration varies between sources
- Reports of patients taking 10 times the intended dose due to confusion between unit measurements
- Hospitalizations from dosing errors with compounded versions are well documented
- The FDA and poison control centers have issued specific warnings
Contamination Risks
- Sterility depends on the compounding pharmacy's quality control
- Contamination has caused infections in some cases
- 503b outsourcing facilities have stricter requirements than 503a pharmacies
Unstudied Combinations
- Many compounded versions combine GLP-1 with other substances (B12, glycine, taurine, lipotropics)
- These combinations are not studied for safety or efficacy
- Reactions to combinations rather than the GLP-1 itself can occur
Lack of Insurance Coverage
- Compounded versions are typically not covered by insurance
- Patients pay out of pocket
- This creates financial burden and incentive to seek the cheapest source — often the riskiest
Limited Recourse for Problems
- Less established adverse event reporting
- Manufacturer accountability less clear
- No standardized patient education materials
- Variable quality of telehealth supervision
Why Some Patients Still Pursue Compounded Versions
Real challenges drive patients to compounded versions:
- Cost (uninsured or high copays)
- Insurance denials
- Continued difficulty accessing branded products
- Telehealth convenience
- Lower-dose customization not available in branded products
These are legitimate concerns. The challenge is balancing them against safety and quality risks.
What to Look For If Considering Compounded Versions
If you decide to use a compounded version, harm reduction principles:
Pharmacy Quality
- Use a 503b outsourcing facility (registered with FDA, more rigorous standards) over a 503a community pharmacy when possible
- Ask about the source of the active ingredient
- Look for state board of pharmacy compliance
- Check for any FDA warning letters or adverse event reports
- Be wary of telehealth platforms that won't tell you which pharmacy fills your prescription
Product
- Avoid products containing salt forms (semaglutide sodium, semaglutide acetate)
- Be skeptical of products combined with unrelated substances
- Ensure clear labeling with concentration and dosing instructions
Clinical Supervision
- Use a prescriber who actually knows you, not just a 5-minute online questionnaire
- Ensure ongoing monitoring (not just initial prescription)
- Have a way to discuss side effects and adjust treatment
- Make sure your other doctors know what you're taking
Self-Administration
- Get clear instructions on dose conversion (mg vs. units, vial concentration)
- Use the right needle size
- Use proper injection technique
- Don't increase doses without medical guidance
- Know which symptoms warrant stopping
Working With Your Doctor
Whether you're using a branded or compounded version, your primary care physician should know about it. We can:
- Help with dosing decisions
- Address side effects (see our GLP-1 side effects guide)
- Monitor for problems
- Help with insurance authorization for branded versions when appropriate
- Address other health considerations
- Coordinate care if specialty consultation is needed
Insurance Authorization for Branded Versions
Many patients can obtain branded versions with insurance coverage if appropriate documentation is provided:
- Medical necessity letters
- Prior authorization with documentation of indication
- Documentation of comorbidities (diabetes, cardiovascular disease, sleep apnea)
- Step therapy documentation
- Appeal processes when initially denied
This is often time-consuming but can substantially reduce out-of-pocket costs.
When to See Your Doctor
- Considering starting a GLP-1 medication
- Currently using a compounded version and want guidance
- Experiencing side effects on any GLP-1 medication
- Confused about dosing or product differences
- Having difficulty obtaining branded medication and weighing options
- Need help with insurance authorization
The FDA's official communications on compounded GLP-1 medications and the American Society of Health-System Pharmacists provide ongoing updates on the regulatory landscape.
Considering or currently using a compounded GLP-1 medication? Contact Zimmer Medical Group for an honest discussion of risks, alternatives, and the right path forward for your specific situation.
